Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02933580 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate Safety, Tolerability, and Pharmacokinetics of JNJ-56136379 in Healthy Japanese Adult Participants
A Phase 1 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT02933580 is a Phase 1 study that has completed, run by Janssen Research & Development. The registered enrollment target is 32 participants.
The verdict
NCT02933580, a Phase 1 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the safety, tolerability, and pharmacokinetics (PK) of JNJ-56136379 in healthy Japanese adult participants following oral administration of single doses from 25 milligram (mg) up to 600 mg, in fasted conditions.
Interventions
- OTHER Placebo
- DRUG JNJ-56136379
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2016-10-12 |
| Est. Completion | 2017-02-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02933580
The ClinicalTrials.gov registry entry for NCT02933580 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02933580 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02933580 about?
NCT02933580 is a clinical study titled "A Study to Investigate Safety, Tolerability, and Pharmacokinetics of JNJ-56136379 in Healthy Japanese Adult Participants". The purpose of this study is to investigate the safety, tolerability, and pharmacokinetics (PK) of JNJ-56136379 in healthy Japanese adult participants following oral administration of single doses from 25 milligram (mg) up to 600 mg, in fasted conditions.
What is the current status of trial NCT02933580?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2016-10-12. Estimated completion is 2017-02-04.
What interventions are being tested in trial NCT02933580?
The interventions under investigation include: Placebo (OTHER), JNJ-56136379 (DRUG).
Who is sponsoring clinical trial NCT02933580?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.